# Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

> **NCT02265913** · PHASE3 · COMPLETED · sponsor: **Padagis LLC** · enrollment: 4076 (actual)

## Conditions studied

- Herpes Labialis

## Interventions

- **DRUG:** Acyclovir 5 percent (Perrigo)
- **DRUG:** Acyclovir 5 percent (Reference)
- **DRUG:** Placebo cream

## Key facts

- **NCT ID:** NCT02265913
- **Lead sponsor:** Padagis LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-06
- **Primary completion:** 2016-04-27
- **Final completion:** 2017-11-21
- **Target enrollment:** 4076 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265913, "Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02265913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*